Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation

Cardiovascular Toxicology

Volumn 4, Issue 2, 2004, Pages 117-131

  Hebert, Valeria Y ^a   Crenshaw, Brian L ^a   Romanoff, Rachelle L ^a   Ekshyyan, Viktoriya P ^a   Dugas, Tammy R ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

3 azido 3 deoxythymidine; Endothelial cells; Endothelin 1; Indinavir; Proliferation; Vascular smooth muscle cells

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR AGONIST; ENDOTHELIN B RECEPTOR AGONIST; INDINAVIR; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CELL PROLIFERATION; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE EXACERBATION; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HEART DEATH; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MITOCHONDRION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL PROLIFERATION; CELL RESPIRATION; CELLS, CULTURED; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENDOTHELIAL CELLS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; MITOCHONDRIA; MYOCYTES, SMOOTH MUSCLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; UMBILICAL VEINS; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 4744368925     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/CT:4:2:117     Document Type: Article

References (48)

1. Sitbon, O., Humbert, M., and Simonneau, G. (2002). Primary pulmonary hypertension: current therapy. Prog. Cardiovasc. Dis. 45:115-128.
2. Barbaro, G., Fisher, S.D., Giancaspro, G., and Lipshultz, S.E. (2001). HIV-associated cardiovascular complications: a new challenge for emergency physicians. Am. J. Emerg. Med. 19:566-574.
3. Barbaro, G., Fisher, S.D., and Lipshultz, S.E. (2001). Pathogenesis of HIV-associated cardiovascular complications. Lancet Infect. Dis. 1:115-124.
4. Mehta, N.J., Khan, I.A., Mehta, R.N., and Sepkowitz, D.A. (2000). HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 118:1133-1141.
5. Himelman, R.B., Dohrmann, M., Goodman, P., Schiller, N.B., Starksen, N.F., Warnock, M., et al. (1989). Severe pulmonary hypertension and corpulmonale in the acquired immunodeficiency syndrome. Am. J. Cardiol. 64:1396-1399.
6. Goldsmith, G.H. Jr., Baily, R.G., Brettler, D.B., Davidson, W.R. Jr., Ballard, J.O., Driscol, T.E., et al. (1988). Primary pulmonary hypertension in patients with classic hemophilia. Ann. Intern. Med. 108:797-799.
7. Speich, R., Jenni, R., Opravil, M., and Jaccard, R. (2001). Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss. Med. Wkly. 131:663-665.
8. Mette, S.A., Palevsky, H.I., Pietra, G.G., Williams, T.M., Bruder, E., Prestipino, A.J., et al. (1992). Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am. Rev. Respir. Dis. 145:1196-1200.
9. Humbert, M. (1998). Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur. Respir. J. 11:554-559.
10. Barbaro, G. and Lipshultz, S.E. (2001). Pathogenesis of HIV-associated cardiomyopathy. Ann. NY Acad. Sci. 946:57-81.
11. Pellicelli, A.M., Palmieri, F., Cicalini, S., and Petrosillo, N. (2001). Pathogenesis of HIV-related pulmonary hypertension. Ann. NY Acad. Sci. 946:82-94.
12. Ehrenreich, H.P., Rieckmann, F., Sinowatz, F., Weich, K.A., Arthur, L.O., Goebel, F.D., et al. (1993). Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein. J. Immunol. 150:4601-4609.
13. Rerkpattanapipat, P.N., Wongpraparut, L.E., Jacobs, L.E., and Kotler, M.N. (2000). Cardiac manifestations of acquired immunodeficiency syndrome. Arch. Intern. Med. 160:602-608.
14. Pugliese, A., Isnardi, D., Saini, A., Scarabelli, T., Raddino, R., and Torre, D. (2000). Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J. Infect. 40:282-284.
15. Coplan, N.L., Shimony, R.Y., Ioachim, H.L., Wilentz, J.R., Posner, D.H., Lipschitz, A., et al. (1990). Primary pulmonary hypertension associated with human immunodeficiency viral infection. Am. J. Med. 89:96-99.
16. Nagaoka, T., Muramatsu, M., Sato, K., McMurtry, I., Oka, M., and Fukuchi, Y. (2001). Mild hypoxia causes severe pulmonary hypertension in fawn-hooded but not in Tester Moriyama rats. Respir. Physiol. 127:53-60.
17. Blumberg, F.C., Lorenz, C. Wolf, K., Sandner, P., Riegger, G. A., and Pfeifer, M. (2002). Increased pulmonary prostacyclin synthesis in rats with chronic hypoxic pulmonary hypertension. Cardiovasc. Res. 55:171-177.
18. Zamora, M.R., Stelzner, T.J., Webb, S., Panos, R.J., Ruff, L.J., and Dempsey, E.C. (1996). Overexpression of endothelin-1 and enhanced growth of pulmonary artery smooth muscle cells from fawn-hooded rats. Am. J. Physiol. 270 (1 Pt 1):L101-L109.
19. De Nucci, G., Thomas, R., D'Orleans-Juste, P., Antunes, E., Walder, C., Warner, T.D., et al. (1988). Presser effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc. Natl. Acad. Sci. USA 85:9797-9800.
20. Hasunuma, K., Rodman, D.M., O'Brien, R.F., and McMurtry, I.F. (1990). Endothelin 1 causes pulmonary vasodilation in rats. Am. J. Physiol. Heart Circ. Physiol. 259:H48-H54.
21. Ivy, D.D., McMurtry, I.F., Yanagisawa, M., Gariepy, C.E., Le Cras, T.D., Gebb, et al. (2001). Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. Am. J. Physiol. Cell Mol. Physiol. 280: L1040-L1048.
22. Yuki, K., Miyauchi, T., Kakinuma, Y., Murakoshi, N., Suzuki, T., Hayashi, J., et al. (2000). Mitochondrial dysfunction increases expression of endothelin-1 and induces apoptosis through caspase-3 activation in rat cardiomyocytes in vitro. J. Cardiovasc. Pharmacol. 36(5 Suppl 1): S205-S208.
23. Schiffren, E.L. (1998). Endothelin: role in hypertension. Biol. Res. 31:199-208.
24. Warner, T.D. (1999). Relationships between the endothelin and nitric oxide pathways. Clin. Exp. Pharmacol. Physiol. 26:247-252.
25. Kvietys, P.R. and Granger, D.N. (1997). Endothelial cell monolayers as a tool for studying microvascular pathophysiology. Am. J. Physiol. 273:G1189-G1199.
26. Yoshida, N., Granger, D.N., Andersen, D.C., Rothlein, R., Lane, C., and Kvietys, P.R. (1992). Anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 262:H1891-H1898.
27. Morshed, K.M., Jain, S.K., and McMartin, K.E. (1994). Acute toxicity of propylene glycol: an assessment using cultured proximal tubule cells of human origin. Fundam. Appl. Toxicol. 23:38-43.
28. McMartin, K.E. and Cenac, T.A. (2000). Toxicity of ethylene glycol metabolites in normal human kidney cells. Ann. NY Acad. Sci. 919:315-317.
29. Dugas, T.R., Kanz, M.F., Hebert, V.Y., Hennard, K.L., Liu, H., Santa Cruz, V., et al. (2004). Vascular medial hyperplasia following chronic, intermittent exposure to 4,4′-methylenedianiline. Cardiovasc. Toxicol. 4:85-96.
30. Dugas, T.R., Jones, B.C., Mifflin, R.C., Santa Cruz, V., Boor, P.J., and Kanz, M.F. (2002). Vascular smooth muscle cell proliferation following chronic, intermittent exposure to 4,4′-methylenedianiline. Toxicol. Sci. 66(1-S):288.
31. Huong, P.L., Kolk, A.H., Eggelte, T.A., Verstijnen, C.P., Gilis, H., and Hendriks, J.T. (1991). Measurement of antigen specific lymphocyte proliferation using 5-bromodeoxyuridine incorporation. An easy and low cost alternative to radioactive thymidine incorporation. J. Immunol. Methods 140:243-248.
32. Shamoto-Nagai, M., Maruyama, W., Kato, Y., Isobe, K., Tanaka, M., Naoi, M., et al. (2003). An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J. Neurosci. Res. 74:589-597.
33. Hurley, J.V. and Jago, M.V. (1975). Pulmonary oedema in rats given dehydromonocrotaline: a topographic and electron-microscope study. J. Pathol. 117:23-32.
34. Rubin, L.J. (1997). Primary pulmonary hypertension. N. Engl. J. Med. 336:111-117.
35. Shimokawa, H. (1998). Endothelial dysfunction in hypertension. J. Atheroscl. Thromb. 4:118-127.
36. Nabel, E.G. (1991). Biology of the impaired endothelium. Am. J. Cardiol. 68:6C-8C.
37. Liu, Z., Wildhirt, S.M., Weismuller, S., Schultze, C., Conrad, N., and Reichart, B. (1998), Nitric oxide and endothelin in the development of cardiac allograft vasculopathy. Potential targets for therapeutic interventions. Atherosclerosis 140:1-14.
38. Gaine, S.P. and Rubin, L.J. (1998). Primary pulmonary hypertension. Lancet 352:719-725.
39. Chi, D., Henry, J., Kelley, J., Thorpe, R., Smith, J.K., and Krishnaswamy, G. (2000). The effects of HIV infection on endothelial function. Endothelium 7:223-242.
40. Zamora, M.A., Dempsey, E.G., Walchak, S.J., and Stelzner, T.J. (1993). BQ123, an ETA receptor antagonist, inhibits endothelin-1 mediated proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 9:429-433.
41. Veyssier-Belot, C. and Cacoub, P. (1999). Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension. Cardiovasc. Res. 44:274-282.
42. Solas, C., Basso, S., Poizot-Martin, I., Ravaux, I., Gallais, H., Gastaut, J.A., et al. (2002). High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J. Acquir. Immune Defic. Syndr. 29:374-377.
43. Cremieux, A.C., Katlama, C., Gillotin, C., Demarles, D., Yuen, G.J., and Raffi, F. (2001). A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1 infected adults. Pharmacotherapy 21:424-430.
44. Yuhki, K.I., Miyauchi, T., Kakinuma, Y., Murakoshi, N., Maeda, S., Goto, K., et al. (2001). Endothelin-1 production is enhanced by rotenone, a mitochondrial complex I inhibitor, in cultured rat cardiomyocytes. J. Cardiovasc. Pharmacol. 38:850-858.
45. Jankov, R.P., Beicastro, R., Ovcina, E., Lee, J., Massaeli, H., Lye, S.J., et al. (2002). Thromboxane A(2) receptors mediate pulmonary hypertension in 60% oxygen-exposed newborn rats by a cyclooxygenase-independent mechanism. Am. J. Respir. Crit. Care Med. 166:208-214.
46. Benbrik, E., Chariot, P., Bonavaud, S., Ammi-Said, M., Frisdal, E., Key, C., et al. (1997). Cellular and mitochondrial toxicity of zidovudine (AZT) didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J. Neurol Sci. 149:19-25.
47. Brown, G.C. and Cooper, C.E. (1994). Nanomolar concentrations of NO reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Lett. 356:295-298.
48. Brown, G.C. and Borutaite, V. (2002). Nitric oxide inhibition of mitochondrial respiration and its role in cell death. Free. Radic. Biol. Med. 33:1440-1450.